EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.

Abstract

Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard chemotherapy to personalized, targeted therapy. First-, second- and third-generation EGFR tyrosine kinase inhibitors (TKIs) are now available for the treatment of EGFR-mutant NSCLC patients. This review will focus on the clinical development of first- and second-generation EGFR TKIs. We will emphasize on essential points like the head-to-head comparison among EGFR TKIs, their activity on brain metastases, mechanisms of resistance, as well as their combination with anti-angiogenic compounds, other targeted therapies, or immunotherapy. The efficacy of first- and second-generation EGFR TKIs in early-stage EGFR-mutant NSCLC will be also finally reviewed.

• Authors: Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell
• Journal: Translational cancer research (Transl Cancer Res) Vol. 8 Issue Suppl 1 Pg. S23-S47 (Jan 2019) ISSN: 2219-6803 [Electronic] China
• PMID: 35117062 (Publication Type: Journal Article, Review)
• Copyright: 2019 Translational Cancer Research. All rights reserved.